Developer docs
API playgroundTry for free, no card

Search company profiles

BlueOcean Ventures

Full company profile

uuid0008xib

Namestring
BlueOcean Ventures
Legal namestring
BlueOcean Ventures SA
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BlueOcean Ventures is a Swiss venture capital investment firm founded in 2007 (actively investing since 2008) that manages two institutional funds dedicated to early-stage medical device and life science companies in Switzerland and Europe. The firm is headquartered in Plan-les-Ouates (Geneva), Switzerland, with its BlueOcean Ventures LP fund registered in Jersey, and operates with 51-100 employees. Its core products are BlueOcean Ventures I, a CHF 25 million private equity fund launched in October 2015, and BlueOcean Ventures II, the first tokenized medtech VC fund launched in October 2018 via the SwissVCToken STO platform and the BOV Token. BlueOcean typically invests CHF 200k to CHF 3M per company at Seed or Series A stages, with target pre-money valuations of CHF 3-10M, and has built a portfolio of 15+ companies including Rheon Medical, Abionic, Ava, CyanoGuard, Luciole Medical, and MIKAJAKI.

The firm's revenue model is standard venture capital economics: management fees charged on fund assets plus carried interest from successful portfolio exits. Fund I attracted Swiss and foreign family offices and Swiss pension fund Prévoyance Santé Valais (PRESV) as anchor LPs, while Fund II broadened investor access via tokenized ownership, accepting both cryptocurrency and fiat from qualified and accredited investors. Distribution is conducted through direct fund investments, co-investment arrangements with family offices, and the SwissVCToken platform. Go-to-market for deal flow relies on deep institutional integration with Innosuisse (Swiss Confederation's Innovation Promotion Agency), FONGIT (Geneva's premier incubator where GP Emmanuel de Watteville heads startup financing), and Swiss Federal Institutes EPFL and ETHZ, providing privileged access to university spin-offs and early-stage Swiss medtech innovation.

BlueOcean's competitive differentiation rests on its four General Partners (Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz, Thomas Zehnder), who collectively have coached, created, managed, or financed over 200 high-tech startups. The firm positions itself as 'entrepreneurs supporting entrepreneurs,' providing hands-on board-level coaching rather than purely financial capital. Scientific advisors include Christophe Saam (founder of patent firm P&TS and Federal Patent Court judge) and Nikos Stergiopulos (EPFL professor with 20+ patents and founder of EndoArt, acquired by Allergan). Portfolio companies have achieved notable regulatory milestones including Rheon Medical's CE Mark and FDA Breakthrough Device Designation for its eyeWatch glaucoma system, Abionic's FDA registration for the abioSCOPE allergy platform, and MIKAJAKI's CE marking for its ophthalmic diagnostic platform.

Short descriptiontext

BlueOcean Ventures is a Swiss venture capital firm managing two funds dedicated to early-stage medical device, life science, and digital health companies in Switzerland and Europe. It invests CHF 200k-3M per company at Seed/Series A, with Fund II notably structured as the first tokenized medtech VC fund via SwissVCToken.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, medical device financing, life sciences funding, seed stage investing, tokenized investment fund
Industry1 code
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Private Equity Fund Management
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees and Carried Interest
TypeManaged Services
Description

BlueOcean Ventures generates returns through management fees charged on the fund assets and carried interest from successful portfolio company exits. The fund structure attracts family offices, pension funds, and high net worth individuals seeking exposure to Swiss hi-tech early stage companies.

blueocean-ventures.com
2Tokenized Fund Revenue
TypeLicensing Royalties
Description

BlueOcean Ventures II launched SwissVCToken, allowing token holders to gain profit from startup investments through a dedicated STO platform. The BOV Token is backed by real assets and based on the value of existing portfolio companies.

blueocean-ventures.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Seed and Series A investments with CHF 200k-3M capital requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Pre-money company valuation (first round) is typically CHF 3 to 10 million. Capital requirements range from CHF 200k to CHF 3M per investment.

blueocean-ventures.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1SwissVCToken
Description

STO platform dedicated to the sale of the BlueOcean Ventures II BOV Token, allowing qualified and accredited investors to indirectly gain profit from BlueOcean Ventures II's portfolio companies.

blueocean-ventures.com
+2 more records
Core offering1 text field

BlueOcean Ventures is a Swiss venture capital investment firm that manages two private equity funds (BlueOcean Ventures I and II) dedicated to providing Seed and Series A capital to early-stage medical device, diagnostics, life sciences, digital health, and nanotechnology companies in Switzerland and Europe. Beyond capital, the firm's four General Partners provide hands-on strategic, operational, and board-level support, leveraging a broad network of experts and industry contacts. BlueOcean Ventures II is distinguished by being the first tokenized medtech VC fund, distributing exposure to investors via the SwissVCToken STO platform and the asset-backed BOV Token.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BlueOcean Ventures operates as a venture capital investment firm managing two investment funds (BlueOcean Ventures I and II) dedicated to early stage medical device and life science companies in Switzerland and Europe. BlueOcean Ventures II is notable for being the first tokenized medtech VC fund, offering the SwissVCToken platform and BOV Token for qualified investors to gain exposure to the portfolio. The firm's investment strategy focuses on companies in medical devices, diagnostics, life sciences, digital health, and nanotechnologies, typically investing CHF 200k to 3M per company at seed or Series A stages with pre-money valuations of CHF 3 to 10 million.

Product and service4 records
1BlueOcean Ventures I
CategoryVenture Capital Fund
Description

A private equity fund dedicated to investing in Swiss Hi-Tech early stage medical device and life science projects. The fund targets investments in companies with CHF 3-10 million pre-money valuation at Seed or Series A stage, with typical capital requirements of CHF 200k to 3M per company. It is offered to institutional investors, family offices, and qualified individual investors.

2BlueOcean Ventures II
CategoryVenture Capital Fund
Description

A tokenized private equity fund that invests in early stage medical device, diagnostics, life sciences, digital health and nanotech companies in Switzerland and Europe. BlueOcean Ventures II is the first tokenized medtech VC fund, distributed via the SwissVCToken platform with both cryptocurrency and fiat payment options for qualified and accredited investors.

3SwissVCToken Platform
CategoryDigital Investment Platform
Description

An STO platform dedicated to the sale of the BlueOcean Ventures II BOV Token, allowing qualified and accredited investors to indirectly gain profit from BlueOcean Ventures II's portfolio companies through tokenized ownership. Supports both cryptocurrency and fiat payment options.

4BOV Token
CategoryDigital Security Token
Description

A security token backed by real assets and based on the value of BlueOcean Ventures II's existing portfolio companies, enabling qualified and accredited investors to participate in the medtech VC fund through cryptocurrency or fiat payment options.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1SECA
Strategic tierMinorTypeOthers
Description

Swiss Private Equity & Corporate Finance Association - Industry partner providing networking and industry association benefits

2Startup Invest
Strategic tierMinorTypeOthers
Description

Platform connecting investors with startups - industry partner for deal flow visibility

Strategic tierMinorTypeOthers
Description

Auditor of BlueOcean Ventures II fund - provides independent financial auditing services

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Switzerland's premier innovation incubator based in Geneva. Emmanuel de Watteville serves as Head of Startup financing at FONGIT, providing deep deal flow access and startup support infrastructure

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Swiss patent and trademark law firm founded by Christophe Saam, BlueOcean's scientific advisor. Provides IP advisory services to portfolio companies

Strategic tierMinorTypeOthers
Description

World-leading provider of fiduciary and administration services for fund operations

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing research talent and technology transfer opportunities. Multiple portfolio companies are EPFL spin-offs including Rheon Medical and Abionic

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing research talent and technology transfer opportunities. BlueOcean founders and advisors have connections from ETHZ

Strategic tierMinorTypeStrategic or Co-development Partner
Description

World-class startup support program Swiss Made - provides additional deal flow and startup development resources

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Candidates are sourced early as a result of BlueOcean's deep involvement with Innosuisse. Former Vice Chairman Faris Sabeti has large relevant network through this relationship

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European venture capital firm investing across technology and life sciences, including medical devices and digital health. Comparable as a broader incumbent that competes with BlueOcean for European medtech deals, with larger fund vehicles and broader geographic reach.

TypeDirect peer
Description

Swiss/European venture capital firm focused exclusively on early- and growth-stage medical device and digital health companies. Directly comparable to BlueOcean given its medtech specialization, European footprint, and similar ticket sizes at Series A/B.

TypeDirect peer
Description

Spanish-based venture capital firm focused exclusively on early- and mid-stage life sciences companies (biotech and medtech). Direct peer in European sector-specialist life sciences VC, with comparable fund sizes and stage focus to BlueOcean.

TypeBroad incumbent
Description

Paris-based European leader in life sciences venture capital across medtech, biotech, and digital health. Comparable as a broader incumbent in the same European medtech/life sciences category that BlueOcean targets, though operating at much larger fund scale.

TypeDirect peer
Description

European life sciences venture capital firm specializing in early- and growth-stage medtech and biotech companies. Direct peer in the European early-stage medtech category, competing for similar Seed/Series A opportunities.

TypeDirect peer
Description

Paris-based venture capital firm with a strong healthcare and life sciences franchise. Comparable as a European life sciences investor with similar stage orientation, though operating with a broader sector mandate than BlueOcean's medtech-only focus.

TypeDirect peer
Description

Swiss/German venture capital firm specializing in early- to mid-stage life sciences and medical technology companies. Direct peer given overlapping European medtech focus, similar stage orientation, and comparable fund sizes to BlueOcean.

TypeBroad incumbent
Description

Leading European life sciences venture capital firm focused on biotech and medtech. Comparable as a broader incumbent investor in the European medtech/life sciences category where BlueOcean competes for deals at the early stages.

TypeDirect peer
Description

European life sciences venture capital firm affiliated with EMBL, investing in early-stage biotech and medtech spinouts. Comparable given its European focus and academic/incubator deal sourcing model similar to BlueOcean's EPFL/ETHZ/FONGIT pipeline.

TypeDirect peer
Description

Swiss-based healthcare-focused investment firm managing public and private medtech/biotech portfolios. Highly comparable to BlueOcean given its Swiss domicile and healthcare-only investment focus, though it operates at significantly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment17 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BlueOcean Ventures

Venture Capital / Private Equity Fund Managementblueocean-ventures.com

BlueOcean Ventures is a Swiss venture capital firm managing two funds dedicated to early-stage medical device, life science, and digital health companies in Switzerland and Europe. It invests CHF 200k-3M per company at Seed/Series A, with Fund II notably structured as the first tokenized medtech VC fund via SwissVCToken.

What BlueOcean Ventures does

BlueOcean Ventures is a Swiss venture capital investment firm founded in 2007 (actively investing since 2008) that manages two institutional funds dedicated to early-stage medical device and life science companies in Switzerland and Europe. The firm is headquartered in Plan-les-Ouates (Geneva), Switzerland, with its BlueOcean Ventures LP fund registered in Jersey, and operates with 51-100 employees. Its core products are BlueOcean Ventures I, a CHF 25 million private equity fund launched in October 2015, and BlueOcean Ventures II, the first tokenized medtech VC fund launched in October 2018 via the SwissVCToken STO platform and the BOV Token. BlueOcean typically invests CHF 200k to CHF 3M per company at Seed or Series A stages, with target pre-money valuations of CHF 3-10M, and has built a portfolio of 15+ companies including Rheon Medical, Abionic, Ava, CyanoGuard, Luciole Medical, and MIKAJAKI.

The firm's revenue model is standard venture capital economics: management fees charged on fund assets plus carried interest from successful portfolio exits. Fund I attracted Swiss and foreign family offices and Swiss pension fund Prévoyance Santé Valais (PRESV) as anchor LPs, while Fund II broadened investor access via tokenized ownership, accepting both cryptocurrency and fiat from qualified and accredited investors. Distribution is conducted through direct fund investments, co-investment arrangements with family offices, and the SwissVCToken platform. Go-to-market for deal flow relies on deep institutional integration with Innosuisse (Swiss Confederation's Innovation Promotion Agency), FONGIT (Geneva's premier incubator where GP Emmanuel de Watteville heads startup financing), and Swiss Federal Institutes EPFL and ETHZ, providing privileged access to university spin-offs and early-stage Swiss medtech innovation.

BlueOcean's competitive differentiation rests on its four General Partners (Faris Sabeti, Emmanuel de Watteville, Sacha Haymoz, Thomas Zehnder), who collectively have coached, created, managed, or financed over 200 high-tech startups. The firm positions itself as 'entrepreneurs supporting entrepreneurs,' providing hands-on board-level coaching rather than purely financial capital. Scientific advisors include Christophe Saam (founder of patent firm P&TS and Federal Patent Court judge) and Nikos Stergiopulos (EPFL professor with 20+ patents and founder of EndoArt, acquired by Allergan). Portfolio companies have achieved notable regulatory milestones including Rheon Medical's CE Mark and FDA Breakthrough Device Designation for its eyeWatch glaucoma system, Abionic's FDA registration for the abioSCOPE allergy platform, and MIKAJAKI's CE marking for its ophthalmic diagnostic platform.

BlueOcean Ventures firmographics

Firmographics
Name
BlueOcean Ventures
Legal name
BlueOcean Ventures SA
Website
https://blueocean-ventures.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
BlueOcean Ventures is a Swiss venture capital firm managing two funds dedicated to early-stage medical device, life science, and digital health companies in Switzerland and Europe. It invests CHF 200k-3M per company at Seed/Series A, with Fund II notably structured as the first tokenized medtech VC fund via SwissVCToken.
Ownership category
akta.pro rank

Where BlueOcean Ventures is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

BlueOcean Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Management Fees and Carried Interest: BlueOcean Ventures generates returns through management fees charged on the fund assets and carried interest from successful portfolio company exits. The fund structure attracts family offices, pension funds, and high net worth individuals seeking exposure to Swiss hi-tech early stage companies.
  2. Tokenized Fund Revenue: BlueOcean Ventures II launched SwissVCToken, allowing token holders to gain profit from startup investments through a dedicated STO platform. The BOV Token is backed by real assets and based on the value of existing portfolio companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractSeed and Series A investments with CHF 200k-3M capital requirements

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

BlueOcean Ventures product offering

Product offering

Core offering

BlueOcean Ventures is a Swiss venture capital investment firm that manages two private equity funds (BlueOcean Ventures I and II) dedicated to providing Seed and Series A capital to early-stage medical device, diagnostics, life sciences, digital health, and nanotechnology companies in Switzerland and Europe. Beyond capital, the firm's four General Partners provide hands-on strategic, operational, and board-level support, leveraging a broad network of experts and industry contacts. BlueOcean Ventures II is distinguished by being the first tokenized medtech VC fund, distributing exposure to investors via the SwissVCToken STO platform and the asset-backed BOV Token.

Product overview

BlueOcean Ventures operates as a venture capital investment firm managing two investment funds (BlueOcean Ventures I and II) dedicated to early stage medical device and life science companies in Switzerland and Europe. BlueOcean Ventures II is notable for being the first tokenized medtech VC fund, offering the SwissVCToken platform and BOV Token for qualified investors to gain exposure to the portfolio. The firm's investment strategy focuses on companies in medical devices, diagnostics, life sciences, digital health, and nanotechnologies, typically investing CHF 200k to 3M per company at seed or Series A stages with pre-money valuations of CHF 3 to 10 million.

Differentiator

Problem solved

Functional benefit

Brands

  • SwissVCToken: STO platform dedicated to the sale of the BlueOcean Ventures II BOV Token, allowing qualified and accredited investors to indirectly gain profit from BlueOcean Ventures II's portfolio companies.
  • BlueOcean Ventures I
  • BlueOcean Ventures II

Products and services

  • BlueOcean Ventures I A private equity fund dedicated to investing in Swiss Hi-Tech early stage medical device and life science projects. The fund targets investments in companies with CHF 3-10 million pre-money valuation at Seed or Series A stage, with typical capital requirements of CHF 200k to 3M per company. It is offered to institutional investors, family offices, and qualified individual investors.
  • BlueOcean Ventures II A tokenized private equity fund that invests in early stage medical device, diagnostics, life sciences, digital health and nanotech companies in Switzerland and Europe. BlueOcean Ventures II is the first tokenized medtech VC fund, distributed via the SwissVCToken platform with both cryptocurrency and fiat payment options for qualified and accredited investors.
  • SwissVCToken Platform An STO platform dedicated to the sale of the BlueOcean Ventures II BOV Token, allowing qualified and accredited investors to indirectly gain profit from BlueOcean Ventures II's portfolio companies through tokenized ownership. Supports both cryptocurrency and fiat payment options.
  • BOV Token A security token backed by real assets and based on the value of BlueOcean Ventures II's existing portfolio companies, enabling qualified and accredited investors to participate in the medtech VC fund through cryptocurrency or fiat payment options.

Companies that use BlueOcean Ventures

Customer profile

Segments4 records

Ideal customer profiles2 records

BlueOcean Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BlueOcean Ventures partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • SECAminorOthersSwiss Private Equity & Corporate Finance Association - Industry partner providing networking and industry association benefits
  • Startup InvestminorOthersPlatform connecting investors with startups - industry partner for deal flow visibility
  • Grant ThorntonminorOthersAuditor of BlueOcean Ventures II fund - provides independent financial auditing services
  • FongitcoreStrategic or Co-development PartnerSwitzerland's premier innovation incubator based in Geneva. Emmanuel de Watteville serves as Head of Startup financing at FONGIT, providing deep deal flow access and startup support infrastructure
  • P&TS (Patent & Trademark Firm)coreImplementation/ SI/ Consulting PartnerSwiss patent and trademark law firm founded by Christophe Saam, BlueOcean's scientific advisor. Provides IP advisory services to portfolio companies
  • OcorianminorOthersWorld-leading provider of fiduciary and administration services for fund operations
  • EPFL (Swiss Federal Institute of Technology Lausanne)coreStrategic or Co-development PartnerAcademic partner providing research talent and technology transfer opportunities. Multiple portfolio companies are EPFL spin-offs including Rheon Medical and Abionic
  • ETHZ (Swiss Federal Institute of Technology Zurich)coreStrategic or Co-development PartnerAcademic partner providing research talent and technology transfer opportunities. BlueOcean founders and advisors have connections from ETHZ
  • VentureLabminorStrategic or Co-development PartnerWorld-class startup support program Swiss Made - provides additional deal flow and startup development resources
  • Innosuisse (Swiss Confederation's Innovation Promotion Agency)coreStrategic or Co-development PartnerCandidates are sourced early as a result of BlueOcean's deep involvement with Innosuisse. Former Vice Chairman Faris Sabeti has large relevant network through this relationship

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

BlueOcean Ventures competitors and assessment

Company assessment

Broad incumbents

  • Wellington Partners: European venture capital firm investing across technology and life sciences, including medical devices and digital health. Comparable as a broader incumbent that competes with BlueOcean for European medtech deals, with larger fund vehicles and broader geographic reach.
  • Sofinnova Partners: Paris-based European leader in life sciences venture capital across medtech, biotech, and digital health. Comparable as a broader incumbent in the same European medtech/life sciences category that BlueOcean targets, though operating at much larger fund scale.
  • Forbion: Leading European life sciences venture capital firm focused on biotech and medtech. Comparable as a broader incumbent investor in the European medtech/life sciences category where BlueOcean competes for deals at the early stages.

Direct peers

  • Endeavour Vision: Swiss/European venture capital firm focused exclusively on early- and growth-stage medical device and digital health companies. Directly comparable to BlueOcean given its medtech specialization, European footprint, and similar ticket sizes at Series A/B.
  • Ysios Capital: Spanish-based venture capital firm focused exclusively on early- and mid-stage life sciences companies (biotech and medtech). Direct peer in European sector-specialist life sciences VC, with comparable fund sizes and stage focus to BlueOcean.
  • Vesalius Biocapital: European life sciences venture capital firm specializing in early- and growth-stage medtech and biotech companies. Direct peer in the European early-stage medtech category, competing for similar Seed/Series A opportunities.
  • Seventure Partners: Paris-based venture capital firm with a strong healthcare and life sciences franchise. Comparable as a European life sciences investor with similar stage orientation, though operating with a broader sector mandate than BlueOcean's medtech-only focus.
  • BioMedPartners: Swiss/German venture capital firm specializing in early- to mid-stage life sciences and medical technology companies. Direct peer given overlapping European medtech focus, similar stage orientation, and comparable fund sizes to BlueOcean.
  • EMBL Ventures: European life sciences venture capital firm affiliated with EMBL, investing in early-stage biotech and medtech spinouts. Comparable given its European focus and academic/incubator deal sourcing model similar to BlueOcean's EPFL/ETHZ/FONGIT pipeline.
  • HBM Partners: Swiss-based healthcare-focused investment firm managing public and private medtech/biotech portfolios. Highly comparable to BlueOcean given its Swiss domicile and healthcare-only investment focus, though it operates at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

BlueOcean Ventures social profiles

Digital presence

BlueOcean Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BlueOcean Ventures leadership team

Management profile

Number of profiles

Profiles6 records

BlueOcean Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BlueOcean Ventures M&A and investment

M&A and investment

M&A

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueOcean Ventures

What does BlueOcean Ventures do?

BlueOcean Ventures is a Swiss venture capital investment firm that manages two private equity funds (BlueOcean Ventures I and II) dedicated to providing Seed and Series A capital to early-stage medical device, diagnostics, life sciences, digital health, and nanotechnology companies in Switzerland and Europe. Beyond capital, the firm's four General Partners provide hands-on strategic, operational, and board-level support, leveraging a broad network of experts and industry contacts. BlueOcean Ventures II is distinguished by being the first tokenized medtech VC fund, distributing exposure to investors via the SwissVCToken STO platform and the asset-backed BOV Token.

Is BlueOcean Ventures a public or private company?

BlueOcean Ventures is a private company. It is classified as management employee owned and is currently operating.

When was BlueOcean Ventures founded?

BlueOcean Ventures was founded in 2015. It employs 51 to 100 people.

Where is BlueOcean Ventures based?

BlueOcean Ventures is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does BlueOcean Ventures make money?

Two revenue lines are on record. Management Fees and Carried Interest is the primary driver. The others are tokenized Fund Revenue.

Who are BlueOcean Ventures's main competitors?

Broad incumbents on record are Wellington Partners, Sofinnova Partners and Forbion. Direct peers are Endeavour Vision, Ysios Capital, Vesalius Biocapital, Seventure Partners, BioMedPartners, EMBL Ventures and HBM Partners.

Does BlueOcean Ventures have an API?

No public API is recorded for BlueOcean Ventures.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarcaMoneyUGX.ai raises $1 million in seed funding led by Blue Ocean Venture PartnersUGX.ai, a deep-tech startup specializing in smart manufacturing platforms, has raised $1 million in seed funding led by Blue Ocean Venture Partners with participation from several other investors. The company plans to utilize the capital to expand its market presence in India and overseas while enhancing product innovation for its AI-powered enterprise applications. Founded in 2023, UGX.ai serves over 20 enterprise customers in the automotive and electronics sectors.PR NewswireAva - Makers of First Fertility Tracking Sensor Bracelet - Announces Close of $10M Series A RoundAva, a medical technology company focused on women's reproductive health, announced the close of a $9.7 million Series A round led by Polytech Ecosystem Ventures, with participation from Blue Ocean Ventures, Global Sources, and existing investors Swisscom and ZKB. The funding will support further product development, scaling production of the Ava fertility tracking sensor bracelet, advancing clinical research, and expanding into international markets in early 2017. The company, which officially launched its FDA-approved wearable device this July, recently confirmed the first pregnancy attributed to use of the bracelet in the US.FinSMEsSwitzerland, Viroblock Closes Financing RoundViroblock SA, a Swiss anti-viral product developer, completed its Series B equity round led by Fongit Seed Invest with co-investors Initiative Capital Romandie and BlueOcean Ventures. The funds will develop its first anti-viral products, and the company appointed Dr. Jamie Paterson as CEO.